Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Weak Earnings
AIAI Summary
ATAI should now be viewed as a transaction-driven special situation rather than a standalone high-burn biotech, with the Lilly acquisition creating a near-term equity floor and the CVR offering upside only if deal close, milestone, and regulatory execution all hold—making transaction completion and milestone monetization the key investable catalyst.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Weak Earnings
ATAI has ample liquidity and low debt, but persistent operating losses, meaningful cash burn, and an extremely rich sales multiple make the investment case depend on future execution rather than current fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Tight consolidation
- •Support holding
- •Breakout test
ATAI has spent the last month in a tight $7.14-$7.26 consolidation, with buyers defending $7.17-$7.18 and the stock now testing resistance near $7.25-$7.26, but a breakout is not yet confirmed.
Last month's narrow $7.14-$7.26 trading range shows a quiet, catalyst-waiting setup
Sentiment & News
Key News Insights:
- •Takeover scrutiny
- •Analyst upside
- •Psychedelic interest
AtaiBeckley's Lilly takeover has sparked shareholder-fairness scrutiny even as analysts still see modest upside and improving estimates. #M&A
The proposed acquisition likely caps near-term upside near the offer price, while legal review and strategic interest in psychedelic therapies keep sentiment mixed
Similar Companies in Healthcare
Other companies in the same sector with AI ratings